Medidata's sales leap on spike in eClinical demand

Cloud-based eClinical outfit Medidata ($MDSO) swung to 21% revenue growth in the first quarter, and, after hitting a record value in billings, the New York company is expecting sales to keep rolling in 2014.

Revenue came in at $76.6 million on the quarter, beating out the previous year's $63.3 million. Medidata posted billings of $90 million on the quarter, a 43% increase, and grew its customer base by about 8%.

Despite the sales gains, however, a nearly 50% leap in R&D costs ate into Medidata's profits, leaving the company with a $1.8 million net loss after posting $5.7 million in income last year.

But Medidata is expecting big things from 2014 on the revenue front, pointing to a subscription backlog of $177 million, up $21 million from the same period in 2013. And that figure doesn't factor in midyear renewals, the company said, making for another $15 million in coming revenue.

"We are off to a good start to the year and on track to achieving the financial outlook we provided earlier in the year," Chief Financial Officer Cory Douglas said in a statement. "We continue to make disciplined investments to maximize our long-term opportunity to drive platform adoption while advancing our growth trajectory."

- read the results

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.